Medical and Pharmaceutical

From CBD drivers to stoner rats, legal reform continues to push weed research to an all-time high

After a successful ballot measure, a broad set of onlookers focuses on Oregon to gauge the social and economic impacts of licensed psilocybin therapy

Despite cannabis leading to breakthrough moments in symptom reduction, the battle against my parents' stigma is ongoing

As part of National Pain Awareness Week, Canopy's chief medical officer discusses how Canadians are navigating chronic pain with weed

Many of the firm's well-known faces took lumps in the weed sector, mistakes they say set them up for success in psychedelics

The Serious Hope Society is asking Ottawa for an exemption from federal cannabis law. Its landlord and city staff might shutter it before one can be granted

To improve safety and access, officials should heed calls to authorize pharmacies, legitimize compassion clubs and support harm-reduction groups

Partnership goes from 'game-on' to game-over as Aurora exits, refutes wrongdoing

Director and producer David Jakubovic says stigma can be broken with just 5 minutes of being open to science

SoundSelf is a 'technodelic' that has been shown to produce unitative states of consciousness and brain states similar to psilocybin

Psychedelics and holistic products can help battle the mental health crisis, says Rritual president Dr. Mike Hart

Biosynthetic cannabinoids use a fraction of extraction's cost, energy, water and biomass waste

Cannabis is legal in Canada, but four main barriers block marginalized people from accessing the regulated market

Numinus Wellness goes public on the prediction that regulation is coming

Earnings leader Valens was a highlight at the one-day virtual event

The strict regulation of medical cannabis in Canada is causing some patients to get frustrated and self-medicate through the recreational market

State has voted to cap THC potency at 10% for patients under 21, edibles at 200 mg

Cannabimovone was shown to increase sensitivity to insulin

A university-run clinical trial showed a significant reduction of insomnia with minimal side effects

'The number one takeaway from this case is that it is very supportive of a municipality’s ability to govern cannabis businesses'

GemmaCert could prevent mistaken drug busts and benefit medical cannabis patients

The free web service recommends your ideal strains based on a database of product descriptions and over 600 medical articles

Three out of 10 Canadian facilities are now EU GMP certified

The cannabis-based medicine could treat seizures associated with Tuberous Sclerosis Complex

Dr. Ian Mitchell of Kamloops is calling out medical professionals across Canada for spreading misinformation on pot

Stephanie deJager says her weed use and other meds had been documented for years, but last November cannabis appeared in a letter for the first time

Learn what the executive has to say about enforcing the illicit market, and if he's ever smoked weed himself

The Ontario producer will be able to ship anywhere inside the 28-member European Union

InMed Pharmaceuticals has initiated a clinical trial for its epidermolysis bullosa treatment, after regulatory approval in December

Treatments for back pain and hemorrhoids will hit shelves mid-2020, company says

After a unanimous city council vote, Mayor Lisa Helps will write a letter to the province

Mike Dirnt, who has stake in the company, announced the offering of up to US$10 million

Canndoc, a subsidiary of InterCure, will later sell 5 tonnes of cannabis back to Tilray

Intelligence firm Coherent Market Insights say the growth is due to an expanding patient base and nods from authorities

Domestic companies and big international players are already poised to cash in

Almost 19 per cent of survey respondents with depression reported using pot over the last 30 days

Despite medical cannabis being legal since 2010, Washington, D.C., students are still in the dark

RYAH Medtech is gearing up to enter more foreign markets and list on the CSE

Tetra Bio-Pharma’s stock continues to rise after announcing more trials at no additional cost to shareholders

Altas Biotechnologies Inc. donated nearly $300,000 to U of A for research over the next 2 years